Examines the role of practice nurses in the treatment of Parkinson's disease. Stages of drug treatment for the disease; Drug management procedures in each stage; Responsibilities of practice nurses in offering non-drug therapy for patients.Handley, J...
drugs that affect serotonin, such as antidepressants, stimulants, or medicine for migraines or Parkinson's disease. This list is not complete. Other drugs may interact with tramadol, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions ar...
Cymbalta is aselective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI). Duloxetine affects chemicals in the brain that may be unbalanced in people with depression. Cymbalta is used to treatmajor depressive disorderin adults. It is also used to treatgeneral anxiety disorderin adul...
Motor symptoms are a core feature of Parkinson’s disease (PD) and cause a significant burden on patients’ quality of life. Oral levodopa is still the most effective treatment, however, the motor benefits are countered by inherent pharmacologic limitations of the drug. Additionally, with disease...
Rosacea is a chronic inflammatory skin condition that is often more severe in older patients. The main clinical features are erythema, telangiectasia, and
neurodegenerative disorders such as Alzheimer's and Parkinson's disease. The study, published in BioMed Central's open access journalMolecular Neurodegeneration, found that neurons in the brain were protected after treatment with T-type calcium-channel blockers, which are commonly used to treat ...
Monitor patients for signs and symptoms of parkinsonism that may be delayed in onset and managed with supportive care measures. There is limited efficacy information with medications used for the treatment of P...
Dr. Rezai is a neuroscience pioneer who has developed treatments for Parkinson’s disease and other brain disorders. Over the last year we followed this master of the mind as he attempted to delay the progression of Alzheimer’s disease and its worst symptoms using ultrasound. We saw a ...
In yet another surprise attribute of the new class of obesity drugs, scientists have found that GLP-1 receptor agonists can also subdue brain inflammation, giving them a potential ‘superpower’ in the fight against Alzheimer’s and Parkinson’s diseases
The as-needed or treat-and-extend regimen was not associated with a lower risk of MACEs, mortality, or other outcomes compared with the monthly regimen (eTable 10 in the Supplement). A post hoc analysis of subgroups in trials that excluded or included patients with cardiovascular diseases ...